{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:23:09Z","timestamp":1793262189142,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T16:23:40Z","timestamp":1683735820000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor\/Tezacaftor\/Ivacaftor: A Multicenter Cohort Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3880-6814","authenticated-orcid":false,"given":"Vered","family":"Wiesel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-8121","authenticated-orcid":false,"given":"Micha","family":"Aviram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-0264","authenticated-orcid":false,"given":"Meir","family":"Mei-Zahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-0181","authenticated-orcid":false,"given":"Miri","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Prais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-5415","authenticated-orcid":false,"given":"Ronen","family":"Bar-Yoseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-7746","authenticated-orcid":false,"given":"Galit","family":"Livnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Goldbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6909","authenticated-orcid":false,"given":"Itai","family":"Hazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-405X","authenticated-orcid":false,"given":"Inbal","family":"Golan-Tripto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.05.003_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2014.05.008","article-title":"Increasing nontuberculous mycobacteria infection in cystic fibrosis","volume":"14","author":"Bar-On","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.003_bib0002","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/ppul.24913","article-title":"Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta-analysis","volume":"55","author":"Reynaud","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0003","unstructured":"2020 Patient Registry Annual Data Report 2020:100."},{"key":"10.1016\/j.jcf.2023.05.003_bib0004","unstructured":"ECFS Patient Registry n.d."},{"key":"10.1016\/j.jcf.2023.05.003_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jcf.2015.09.007","article-title":"Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis","volume":"15","author":"Qvist","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.003_bib0006","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/apm.12903","article-title":"The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis","volume":"126","author":"Ravnholt","year":"2018","journal-title":"APMIS"},{"key":"10.1016\/j.jcf.2023.05.003_bib0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2023.05.003_bib0008","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1002\/ppul.23825","article-title":"Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward","volume":"52","author":"Martiniano","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.05.003_bib0010","doi-asserted-by":"crossref","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2023.05.003_bib0011","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciac788","article-title":"Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society\/Infectious Disease Society of America Treatment Guidelines","volume":"76","author":"Ku","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2023.05.003_bib0012","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3201\/eid2203.150828","article-title":"Treatment of Mycobacterium abscessus Infection","volume":"22","author":"Novosad","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jcf.2023.05.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.05.003_bib0014","unstructured":"Azithromycin Monograph for Professionals. DrugsCom n.d. https:\/\/www.drugs.com\/monograph\/azithromycin.html (accessed January 24, 2023)."},{"key":"10.1016\/j.jcf.2023.05.003_bib0015","unstructured":"Amikacin Monograph for Professionals. DrugsCom n.d. https:\/\/www.drugs.com\/monograph\/amikacin.html (accessed January 24, 2023)."},{"key":"10.1016\/j.jcf.2023.05.003_bib0016","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.003_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.05.003_bib0018","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1002\/ppul.24522","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","author":"Saiman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.05.003_bib0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2023.05.003_bib0021","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/S1569-1993(21)01887-7","article-title":"463: Clearance of colonized bacterial species in CF patients before and after elexacaftor\/tezacaftor\/ivacaftor","volume":"20","author":"Lenhan","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00724-2021","article-title":"CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011\u20132018","volume":"8","author":"Ricotta","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2023.05.003_bib0023","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1002\/ppul.25637","article-title":"Twelve years of progressive Mycobacterium abscessus lung disease in CF\u2014Response to Trikafta","volume":"56","author":"Gur","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jcf.2023.05.003_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biocel.2014.04.001","article-title":"Understanding how cystic fibrosis mutations disrupt CFTR function: From single molecules to animal models","volume":"52","author":"Wang","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0026","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcf.2014.12.012","article-title":"Clinical expression of patients with the D1152H CFTR mutation","volume":"14","author":"Terlizzi","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.05.003_bib0027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MEG.0b013e3282f36d04","article-title":"The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype","volume":"20","author":"Augarten","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0028","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jcf.2018.06.008","article-title":"The Q359K\/T360K mutation causes cystic fibrosis in Georgian Jews","volume":"17","author":"Mei-Zahav","year":"2018","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2023.05.003_bib0029","doi-asserted-by":"crossref","first-page":"00856","DOI":"10.1183\/23120541.00856-2020","article-title":"Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome","volume":"7","author":"Zampoli","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2023.05.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102248","article-title":"Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review","volume":"65","author":"Figueira","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0031","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41598-021-84525-x","article-title":"Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections","volume":"11","author":"Gloag","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2023.05.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.05.003_bib0033","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","article-title":"NTM drug discovery: status, gaps and the way forward","volume":"23","author":"Wu","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcf.2023.05.003_bib0034","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/microorganisms10071421","article-title":"Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions","volume":"10","author":"Lanni","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.jcf.2023.05.003_bib0035","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1128\/AAC.00986-07","article-title":"Differential Antibiotic Susceptibility of Mycobacterium abscessus Variants in Biofilms and Macrophages Compared to That of Planktonic Bacteria","volume":"52","author":"Greendyke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2023.05.003_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00359","article-title":"Extreme Drug Tolerance of Mycobacterium abscessus \u201cPersisters","volume":"11","author":"Yam","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jcf.2023.05.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.151855","article-title":"Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation","volume":"807","author":"Li","year":"2022","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.jcf.2023.05.003_bib0038","doi-asserted-by":"crossref","first-page":"e01212","DOI":"10.1128\/AAC.01212-19","article-title":"Biofilms of Mycobacterium abscessus Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation","volume":"64","author":"Kolpen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2023.05.003_bib0039","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.48.12.4907-4910.2004","article-title":"A Subinhibitory Concentration of Clarithromycin Inhibits Mycobacterium avium Biofilm Formation","volume":"48","author":"Carter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2023.05.003_bib0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3201\/eid1403.061405","article-title":"Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients","volume":"14","author":"Levy","year":"2008","journal-title":"Israel. Emerg Infect Dis"},{"key":"10.1016\/j.jcf.2023.05.003_bib0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1513\/AnnalsATS.201309-310OC","article-title":"Clinical Significance of a First Positive Nontuberculous Mycobacteria Culture in Cystic Fibrosis","volume":"11","author":"Martiniano","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.05.003_bib0042","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jcf.2023.05.003_bib0043","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:38Z","timestamp":1767240698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323001339"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor\/Tezacaftor\/Ivacaftor: A Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}